Are TERN, CRBG, EQH Obtaining Fair Deals for their Shareholders?

Rhea-AI Summary

{"summary":"","positive":[],"negative":[],"faq":[]}

News Market Reaction – TERN

+0.59%

1 alert

+0.59% News Effect

On the day this news was published, TERN gained 0.59%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Merck cash offer: $53.00 per share CRBG exchange ratio: 1.0000 share CRBG ownership: 51% +2 more

5 metrics

Merck cash offer $53.00 per share Cash consideration for Terns Pharmaceuticals sale to Merck

CRBG exchange ratio 1.0000 share Each Corebridge share exchanged for combined company stock

CRBG ownership 51% Corebridge shareholders’ ownership of combined company post-merger

EQH exchange ratio 1.55516 shares Each Equitable share exchanged for combined company stock

EQH ownership 49% Equitable shareholders’ ownership of combined company post-merger

Market Reality Check

Price: $52.92 Vol: Volume 79,833,144 is 12.1...

high vol

$52.92 Last Close

Volume Volume 79,833,144 is 12.19x the 20-day average of 6,550,296, showing extremely elevated trading ahead of this legal-focused headline. high

Technical Shares at $52.86 are trading above the $21.20 200-day MA and sit very close to the 52-week high of $52.98, indicating a strong pre-existing uptrend into the deal-related news.

Peers on Argus

TERN gained 5.72% while key biotech peers showed mixed moves (e.g., IMTX and NRI...

TERN gained 5.72% while key biotech peers showed mixed moves (e.g., IMTX and NRIX up, RIGL slightly down). Combined with no peers in the momentum scanner and no same-day peer news, today’s action appears company-specific rather than a sector-wide biotech rotation.

Historical Context

5 past events · Latest: Mar 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 25	Acquisition announcement	Positive	+5.7%	Merck agreed to acquire Terns for $53.00 per share in cash.
Feb 25	Investor conferences	Neutral	-1.1%	Participation in multiple March investor conferences was announced.
Feb 02	Inducement grants	Positive	+4.6%	Equity inducement awards and options were granted to new employees.
Jan 07	Pipeline update	Positive	-5.6%	Detailed 2026 priorities and encouraging CARDINAL trial data for TERN-701.
Jan 02	Inducement grants	Neutral	-2.3%	Additional stock options granted under the 2022 Inducement Award Plan.

Pattern Detected

Recent history shows strong positive reactions to major corporate events like the Merck acquisition, but mixed or negative reactions to operational updates and routine disclosures.

Recent Company History

Over recent months, Terns moved from routine corporate updates to a transformative acquisition. An 8-K on Merck’s agreement to acquire Terns for $53.00 per share drove a strong positive reaction. Earlier, the company highlighted 2026 clinical milestones for TERN-701 and reported sizeable cash of about $1.0 billion, yet shares fell on that update. Inducement grant announcements in January and February 2026 produced mixed price responses. Against this backdrop, the law-firm investigation headline overlays an already deal-driven trading environment.

Market Pulse Summary

This announcement highlights a law firm’s investigation into whether the Merck deal at $53.00 per sh...

Analysis

This announcement highlights a law firm’s investigation into whether the Merck deal at $53.00 per share offers fair value to Terns shareholders, a common step following sizeable M&A premiums. Recent history shows Terns transitioning from clinical and strategic updates into a definitive acquisition agreement. Investors may monitor the tender offer process, upcoming SEC communications, and any changes to transaction terms or closing conditions as key markers for how this situation progresses.

Key Terms

federal securities laws, fiduciary duties, contingent fee basis

3 terms

federal securities laws regulatory

"investigating the following companies for potential violations of the federal securities laws"

Federal securities laws are the set of national rules that require companies and market participants to provide accurate information, prohibit deceptive practices, and ensure fair trading of stocks and bonds. Think of them as the rules of the road for financial markets: they help investors make informed choices by mandating disclosures and punishing fraud, which reduces risk and builds trust in the safety and reliability of investments.

fiduciary duties financial

"and/or breaches of fiduciary duties to shareholders relating to"

Fiduciary duties are the legal and ethical responsibilities that company directors, officers, or financial advisors have to put shareholders’ interests ahead of their own, acting with honesty, care, and loyalty. Think of it like a guardian managing someone’s money: choices must prioritize the owner’s benefit, avoid conflicts, and be made with prudent judgment; investors rely on these duties to ensure decisions aren’t self‑serving and to provide grounds for legal action if abused.

contingent fee basis financial

"We would handle any matter on a contingent fee basis, whereby you would not"

A contingent fee basis is an arrangement where payment is made only if a specified outcome is achieved, like a lawyer getting paid only when a lawsuit succeeds or a finder receiving a commission only if a deal closes. For investors, it matters because contingent obligations shift risk off the payer and onto the payee, can reduce upfront costs but create future liabilities or incentives that affect valuations and the alignment of interests — think of it as a “pay-if-success” bet on a specific result.

AI-generated analysis. Not financial advice.

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

The proposed transactions may contain terms that could limit superior competing offers.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

NEW YORK, March 26, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Terns Pharmaceuticals, Inc. (NASDAQ: TERN)'s sale to Merck for $53.00 per share in cash. If you are a Terns shareholder, click here to learn more about your rights and options.

Corebridge Financial, Inc. (NYSE: CRBG)'s merger with Equitable Holdings, Inc. whereby each outstanding share of Corebridge common stock will be exchanged for 1.0000 shares of the combined company's common stock. Upon closing of the proposed transaction, Corebridge shareholders will own approximately 51% of the combined company. If you are a Corebridge shareholder, click here to learn more about your rights and options.

Equitable Holdings, Inc. (NYSE: EQH)'s merger with Corebridge Financial, Inc. whereby each outstanding share of Equitable common stock will be exchanged for 1.55516 shares of the combined company's common stock. Upon closing of the proposed transaction, Equitable shareholders will own approximately 49% of the combined company. If you are an Equitable shareholder, click here to learn more about your legal rights and options.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/are-tern-crbg-eqh-obtaining-fair-deals-for-their-shareholders-302726158.html

SOURCE Halper Sadeh LLP